Overview

• Teladoc Q2 revenue falls 2% to $631.9 mln, but beats analysts' expectations, per LSEG data

• Adjusted EBITDA down 23% to $69.3 mln, also beating expectations

• Co retired $550.6 mln in convertible notes, secured $300 mln credit facility

Outlook

• Teladoc expects full-year 2025 revenue of $2.501 bln to $2.548 bln

• Company projects full-year adjusted EBITDA of $263 mln to $294 mln

• Teladoc anticipates Q3 2025 revenue between $614 mln and $636 mln

• Company forecasts Q3 2025 adjusted EBITDA of $56 mln to $70 mln

Result Drivers

• INTEGRATED CARE GROWTH - Integrated Care segment revenue increased 4% year-over-year, driven by disciplined execution and strategic investments

• BETTERHELP DECLINE - BetterHelp segment revenue fell 9% year-over-year, reflecting challenges in the direct-to-consumer market

• CREDIT FACILITY - Co secured a $300 mln credit facility to enhance financial flexibility, per CEO Chuck Divita

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 22 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy."

• Wall Street's median 12-month price target for Teladoc Health Inc is $8.38, about 2.1% above its July 28 closing price of $8.20

Press Release: ID:nGNXbb3X06

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)